Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How

Advances in Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer: Why, Who, and How (September 2019)

Thursday, September 12, 2019 in Phoenix, AZ
Lunch -- Phoenix Convention Center, 12:30 PM MT
Room 101 AB (West Building, Street Level)

Agenda

Pre-registration is now closed. We welcome you to register on-site at 12:30 PM at the Phoenix Convention Center (100 North 3rd Street), Room 101 AB (West Building, Street Level). Remember to bring your ASCP badge to expedite your registration.

Faculty

Program Director
Howard West, MD

Associate Clinical Professor
City of Hope Comprehensive Cancer Center
Duarte, California

Faculty
Sanjay Mukhopadhyay, MD

Director, Pulmonary Pathology
Department of Pathology
Cleveland Clinic
Cleveland, Ohio

Faculty
Sandip P. Patel, MD

Associate Professor
Division of Hematology and Medical Oncology
UC San Diego Moores Cancer Center
La Jolla, California

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Target Audience
This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Learning Objectives

  • Evaluate the clinical utility of predictive biomarkers for immune checkpoint inhibitor response in lung cancer by line of therapy, available therapeutic alternatives, and health economic considerations
  • Compare and contrast the different methodologies and assays for identifying biomarkers of response to immune checkpoint inhibitors in different lung cancer histologies and treatment settings
  • Implement best practices for biomarker testing/interpretation of results to guide treatment selection in different lung cancer histologies and treatment settings
  • Summarize ongoing research regarding the utility of biomarkers, PD-L1, MSI/MMR, tumor mutational burden, DNA damage repair, T-cell functional state, composite biomarkers, or other host factors predictive of response to and/or toxicities associated with immune checkpoint inhibitors

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology's Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

If you are interested in having us report ABPath MOC, please ensure the following information is provided within your Member Profile:

Name - as registered with ABPath
Date of Birth (Month/Day)
Your ABPath ID number

Learners must complete the post-test with a passing score of 70% and provide additional documentation following the symposium. 

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.